<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a clonal hematopoietic disorder characterized by a hyperproliferative bone marrow, <z:mp ids='MP_0005485'>cellular dysplasia</z:mp>, and ineffective hematopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is composed of several subtypes, the classification of which has evolved over several years </plain></SENT>
<SENT sid="2" pm="."><plain>The treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> involves improving patient survival and quality of life while decreasing the likelihood of progression to <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In addition to supportive care with transfusions and hematopoietic growth factors as well as stem cell transplantation, three chemotherapeutic agents have been approved to treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>--lenalidomide, <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, and <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, multiple agents and novel combinations are currently in development to treat both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Several clinical studies which have investigated these therapeutic approaches, as well as the incorporation of new tools used in the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, have been published since the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition, and are discussed here </plain></SENT>
<SENT sid="6" pm="."><plain>By becoming familiar with these studies, the physician will be better able to provide the optimal treatment for their patients, as well as become aware of novel therapeutic strategies to offer their patients in ongoing clinical trials </plain></SENT>
</text></document>